domains/health/AI compresses drug discovery timelines by 30-40 percent but has not yet improved the 90 percent clinical failure rate that determines industry economics.md

@@ -15,6 +15,12 @@ Insilico Medicine achieved the most significant milestone: positive Phase IIa re
 
 The critical question is whether AI can move the needle beyond Phase I. The pharmaceutical industry's overall ~90% clinical failure rate has not demonstrably changed. "Faster to clinic" is proven; "more likely to work in patients" is not. If AI cracks later-stage success rates, the economic impact dwarfs everything else in healthcare -- a single percentage point improvement in Phase II/III success is worth billions. But the proof is still ahead of us.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-03-19-vida-ai-biology-acceleration-healthspan-constraint]] | Added: 2026-03-19*
+
+Smith 2026 provides concrete evidence of compression magnitude: Ginkgo Bioworks + GPT-5 compressed 150 years of protein engineering into weeks. This is consistent with Amodei's 10-20x prediction (50-100 years → 5-10 years) and confirms that discovery-phase compression is already happening at scale, not speculative.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -89,6 +89,12 @@ Weight regain data shows that even among patients who complete treatment, GLP-1
 
 Aon data shows the 80%+ adherent cohort captures dramatically stronger cost reductions (9 percentage points lower for diabetes, 7 points for weight loss), confirming that adherence is the binding variable for economic viability. The adherence-dependent savings pattern means low persistence rates eliminate cost-effectiveness even when clinical benefits exist.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-03-19-vida-ai-biology-acceleration-healthspan-constraint]] | Added: 2026-03-19*
+
+GLP-1 behavioral adherence failures demonstrate that even breakthrough pharmacology cannot overcome behavioral determinants: patients on GLP-1 alone show same weight regain as placebo without behavior change. This is direct evidence that the 'human constraints' factor (Amodei framework) limits pharmaceutical efficacy independent of drug quality.
+
 ---
 
 Relevant Notes:

domains/health/human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md

@@ -19,6 +19,12 @@ These findings create a genuine paradox for clinical AI deployment. The system d
 
 Wachter frames the challenge directly: "Humans suck at remaining vigilant over time in the face of an AI tool." The Tesla parallel is apt -- a system called "self-driving" that requires constant human attention produces 100+ fatalities from the predictable failure of that attention. Healthcare's "physician-in-the-loop" model faces the same fundamental human factors constraint.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-03-19-vida-ai-biology-acceleration-healthspan-constraint]] | Added: 2026-03-19*
+
+AI-accelerated biology creates a NEW health risk pathway not in the original healthspan constraint framing: clinical deskilling + verification bandwidth erosion. At 20M clinical consultations/month with zero outcomes data and documented deskilling (adenoma detection: 28% → 22% without AI), AI deployment without adequate verification infrastructure degrades the human clinical baseline it's supposed to augment. This extends the healthspan constraint to include AI-induced capacity degradation.
+
 ---
 
 Relevant Notes:

domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md

@@ -59,6 +59,12 @@ While social determinants predict health outcomes in observational studies, RCT
 
 The Diabetes Care perspective provides a specific mechanism example: produce prescription programs may improve food security (a social determinant) without improving clinical outcomes (HbA1c, diabetes control) because the causal pathway from social disadvantage to disease is not reversible through single-factor interventions. This demonstrates the 10-20% medical care contribution in practice—addressing one SDOH factor (food access) doesn't overcome the compound effects of poverty, stress, and social disadvantage.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-03-19-vida-ai-biology-acceleration-healthspan-constraint]] | Added: 2026-03-19*
+
+Amodei's complementary factors framework explicitly identifies 'human constraints' (behavior change, social systems, meaning-making) as a factor that bounds AI returns even in biological science. This provides theoretical grounding for why the 80-90% non-clinical determinants remain unaddressed by AI-accelerated biology—they fall into the 'human constraints' category that AI cannot optimize.
+
 ---
 
 Relevant Notes:

inbox/queue/.extraction-debug/2026-03-19-vida-ai-biology-acceleration-healthspan-constraint.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "ai-accelerated-biology-shifts-healthspan-constraint-composition-toward-behavioral-social-determinants.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "amodei-complementary-factors-framework-predicts-bounded-not-unlimited-ai-health-returns.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "ai-accelerated-biology-shifts-healthspan-constraint-composition-toward-behavioral-social-determinants.md:set_created:2026-03-19",
+      "amodei-complementary-factors-framework-predicts-bounded-not-unlimited-ai-health-returns.md:set_created:2026-03-19"
+    ],
+    "rejections": [
+      "ai-accelerated-biology-shifts-healthspan-constraint-composition-toward-behavioral-social-determinants.md:missing_attribution_extractor",
+      "amodei-complementary-factors-framework-predicts-bounded-not-unlimited-ai-health-returns.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-19"
+}

inbox/queue/2026-03-19-vida-ai-biology-acceleration-healthspan-constraint.md

@@ -7,11 +7,15 @@ date: 2026-03-19
 domain: health
 secondary_domains: [ai-alignment, grand-strategy]
 format: synthesis
-status: unprocessed
+status: enrichment
 priority: high
 tags: [ai-biology-acceleration, healthspan-constraint, belief-disconfirmation, social-determinants, verification-bandwidth, civilizational-health]
 flagged_for_leo: ["This synthesis directly addresses whether healthspan is civilization's binding constraint in the AI era — Leo's civilizational framework needs to incorporate this compositional shift"]
 flagged_for_theseus: ["The Amodei complementary factors framework (physical world speed, data needs, intrinsic complexity, human constraints, physical laws) explains why AI doesn't eliminate behavioral health constraints — Theseus should evaluate whether this framework holds for superintelligence timelines"]
+processed_by: vida
+processed_date: 2026-03-19
+enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "AI compresses drug discovery timelines by 30-40 percent but has not yet improved the 90 percent clinical failure rate that determines industry economics.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -115,3 +119,11 @@ PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcome
 WHY ARCHIVED: Documents the keystone belief disconfirmation search result — Belief 1 survives the AI-acceleration challenge because the 80-90% non-clinical determinants are explicitly excluded from what biology can address, per Amodei's own complementary factors framework.
 
 EXTRACTION HINT: Extract the claim that AI-accelerated biology doesn't change the 80-90%/10-20% split — and that this REINFORCES rather than undermines the importance of non-clinical health infrastructure. The Amodei self-defeat (his framework defeats his own health prediction as sufficient for population health) is the key insight.
+
+
+## Key Facts
+- Ginkgo Bioworks + GPT-5 compressed 150 years of protein engineering into weeks (Smith 2026)
+- Amodei predicts AI will compress 50-100 years of biological progress into 5-10 years
+- Amodei predicts potential lifespan doubling to ~150 years from AI-accelerated biology
+- FDA moving from animal testing to AI models and organ-on-chip (April 2025 roadmap)
+- Aon claims data: AI analysis reveals GLP-1 → 50% ovarian cancer risk reduction in 192K-patient dataset